外周型脊柱关节炎关节与附着点炎症MRI评分系统的效能:CRESPA试验的事后分析
本研究在56例早期外周型脊柱关节炎(pSpA)患者启动TNF抑制剂戈利木单抗前及46例持续临床缓解者随访时行骨盆与下肢MRI,由3名读者应用半定量评分系统评估4类病变。随访时46例中34例(74%)MRI指数下降,15例(33%)达到MRI应答(下降超过最小可检测变化2.8);读者间信度组内相关系数状态评分0.92(95%CI 0.85-0.95)、变化评分0.89(0.80-0.94),MRI指数与CRP等疾病活动指标相关(均P<0.05)。作者结论为该下肢炎症MRI指数在早期pSpA中显示信度、效度和对变化的敏感性。
要点
- MRI下肢炎症指数由75个位点评分(各0-3分)求和,最小可检测变化为2.8。
- 46例随访患者中15例(33%)达到MRI应答,28例有临床下肢受累者中13例(46%)达到。
- 读者间信度组内相关系数状态评分0.92(95%CI 0.85-0.95),变化评分0.89(0.80-0.94)。
核心结论
- 所提出的MRI下肢炎症指数在早期pSpA患者中显示出信度、效度和对变化的敏感性。
研究设计与样本
- CRESPA试验的事后分析,56例早期pSpA患者在启动TNF抑制剂戈利木单抗前行骨盆与下肢MRI,其中46例在24、36或48周达到持续临床缓解后复查。
- 3名读者应用半定量MRI评分系统评估下肢关节与附着点炎症,包括附着点骨炎、附着点软组织炎症、关节骨炎和关节滑膜炎/积液4类病变。
主要发现
- 随访时46例中34例(74%)MRI指数下降,15例(33%)达到MRI应答,即下降超过最小可检测变化2.8。
- 在经MRI评估的下肢部位有临床受累的患者中,28例有13例(46%)达到MRI应答。
- 读者间信度很好,状态评分平均测量组内相关系数0.92(95%CI 0.85-0.95),变化评分0.89(95%CI 0.80-0.94)。
- MRI指数与CRP(Spearman rho 0.41,95%CI 0.23-0.56)、6个关节肿胀关节计数(0.47,95%CI 0.27-0.63)、14个附着点压痛计数(0.32,95%CI 0.12-0.50)和疼痛评分(0.28,95%CI 0.08-0.46)相关,均P<0.05。
关键数值与推荐
- MRI下肢炎症指数为75个位点评分(各0-3分)之和。
- MRI应答定义为MRI下肢炎症指数下降超过最小可检测变化(2.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to investigate the reliability, validity, and sensitivity to change of a novel MRI scoring system in early peripheral SpA (pSpA). METHODS: MRI of the pelvis and lower extremities was performed before initiation of the TNF inhibitor golimumab in 56 patients and repeated in 46 patients who achieved sustained clinical remission after 24, 36 or 48 weeks. Three readers applied a semi-quantitative MRI scoring system for lower-extremity joint and entheseal inflammation. Four lesion types were assessed: entheseal osteitis, entheseal soft-tissue inflammation, joint osteitis, and joint synovitis/effusion. MRI response was defined as a decrease in MRI lower-extremity inflammation index (sum of scores from 75 sites, each scored 0-3) above the smallest detectable change (SDC). RESULTS: At follow-up, the MRI index decreased in 34 of 46 patients (74%), and 15 (33%) patients achieved MRI response, i.e. a decrease above SDC of 2.8. When restricting the analysis to patients with clinical involvement of lower-extremity sites that were assessed by MRI, 13 of 28 (46%) achieved MRI response. Interreader reliability was very good, with an average-measure intraclass correlation coefficient of 0.92 (95% CI: 0.85-0.95) for status scores and 0.89 (0.80-0.94) for change in scores. The MRI index correlated with other measures of disease activity, including CRP [Spearman's rho 0.41 (0.23-0.56)], swollen joint count of 6 joints [0.47 (0.27-0.63)], tender enthesis count of 14 entheses [0.32 (0.12-0.50)] and pain score [0.28 (0.08-0.46)], all P < 0.05. CONCLUSION: The proposed MRI lower-extremity inflammation index demonstrated reliability, validity, and sensitivity to change in patients with early pSpA. TRIAL REGISTRATION: Clinicaltrials.gov, http://clinicaltrials.gov, NCT01426815.
引用
- Krabbe S, Renson T, Jans L, et al. Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial. Rheumatology (Oxford). 2023. PMID: 36200875. doi:10.1093/rheumatology/keac567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。